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ABSTRACT
There is a broad agreement that patient-reported outcome
(PRO) assessment in health care should proceed from a
strong conceptual basis, with rationales clearly articulated in
advance concerning what is to be measured and how this is to
be accomplished. The representation of the patient’s perspec-
tive has been part of clinical trials for some time; but the
formalization of, and broader emphasis on PROs has become
increasingly important with the release of the draft guidance
for industry on patient-reported outcomes. In response, we
address the challenges in constructing the conceptual foun-
dations for PRO assessment to support drug product labeling
claims submitted to regulatory agencies worldwide.
After discussing what constitutes a PRO concept and an
adequate basis for framing a PRO assessment, we examine
the consequences of choosing PRO instruments without ref-
erence to a well-established conceptual framework for mea-
surement. Then we illustrate through a hypothetical example
the important interplay between the sponsor’s proposed
product claim, the corresponding conceptual model that
depicts hypotheses involving the PRO concept(s) in the claim,
and the resulting conceptual framework(s) for measurement
to guide instrument selection and psychometric analyses. We
discuss how these conceptual issues may vary or evolve over
time depending on the phase of product development.
As the science of PRO measurement continues to develop
and experience accumulates, a consensus may emerge on how
best to articulate the conceptual basis of PRO measurement
for purposes of product labeling and regulation. In the mean-
time, one point is imminently clear: in regulatory decisions
expected to affect not only the quantity but the quality of life,
it is imperative to incorporate the patient’s own perspective
on the illness experience and the effects of therapy.
Keywords: conceptual framework, conceptual model, instru-
ment development, patient-reported outcomes.
Introduction
Acknowledgments of the need to capture the patient’s
perspective of the impact of illness and health-care
interventions has grown rapidly over the last decade.
Attention has been paid to selection of measures, analy-
sis (e.g., the impact of missing data), and interpretation
(e.g., deﬁnition of a clinically important difference), but
less so to the conceptual models and frameworks for
hypothesis generation, analysis, and interpretation of
patient-reported outcome (PRO) data.
This article underlines some of the issues that need
to be considered to maximize our understanding of the
meaning of the PRO data. The next section provides
an overview of the use of PRO concepts in health-care
research in drug development. The subsequent two
sections address explicitly deﬁning the conceptual
model for the analysis of a PRO claim and the concep-
tual framework to guide PRO measurement in the
validation of that claim. The last section addresses the
need to update our conceptual models to reﬂect our
understanding of the patient’s perspective in interpret-
ing the impact of disease and treatment.
Some recommendations to apply issues and tech-
niques raised in this article may be preliminary. More
explicit use of conceptual models and frameworks as
tools to guide research will improve interpretation and
communication of research ﬁndings.
What Is a PRO Concept?
“Patient-reported outcome” is a broad term that
includes direct subjective assessment by the patient
of elements of their health including: symptoms,
function, well-being, health-related quality of life
(HRQOL), perceptions about treatment, satisfac-
tion with care received, and satisfaction with pro-
fessional communication. The patient is asked to
summarize his or her evaluation of the disease, treat-
ment, or health-care system interactions through
various modes, providing perceptions related to the
condition, its impact, and its functional implications.
The patient’s perception of the illness experience is
inﬂuenced by internal standards, intrinsic values, and
expectations. The importance to the individual is
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reﬂected in the evaluative comments and ratings. The
PRO provides information unavailable from other
sources. These data reﬂect how the patient interprets
the experience and the conditions not observable by
others and are distinct from proxy measures.
Patient reports can provide insights into health
status with or without a comparator; current functional
capacity comparedwith past performance; the intensity
of symptoms or side effects of treatment; impressions of
how symptoms affect function; ability to comply with
treatment recommendations or rationale for nonadher-
ence; and vivid descriptions of difﬁculties imposed on
personal and family life (e.g., inability to work) [1–3].
To capture these insights from patients in a way that
allows for meaningful communication, rules have been
devised for the measurement of subjective phenomena
[4,5]. These rules, as they apply to PRO assessment in
the regulatory environment and for making claims
about new products, are described in the Food and
Drug Administration (FDA) draft PRO guidance [6].
The PRO concept that is deﬁned in the Guidance is “the
speciﬁc goal of measurement (i.e., the thing that is to be
measured by a PRO instrument)” [6]. PRO concepts
may range from the simple, e.g., pain intensity, to the
complex, e.g., HRQOL, which itself encompasses
several multiple multidimensional concepts. The com-
plexity of the PRO instrument will be driven by the
complexity of the concept being measured. For
example, a simple concept such as pain intensity may be
measured by a single item speciﬁc to that concept, while
a more complex concept such as physical function that
might incorporate aspects of activities of daily living,
mobility, etc., would require multiple items or multiple
domains.Whether the concept beingmeasured is simple
or complex, it is important there be sufﬁcient evidence
that the PRO concept is adequately measured to ensure
appropriate interpretation of scores and clarity of com-
munication of ﬁndings. Issues related to adequacy of
evidence are discussed in more detail in later articles in
this series.
What Is an Adequate Basis for Framing a
PRO Assessment?
Given these considerations, what then is an adequate
basis for framing a PRO assessment? A conceptual
model that clearly deﬁnes the decision-relevant out-
comes of interest and their posited interrelationships
and possible determinants should guide decision-
making. Speciﬁcally, a conceptual model should pro-
vide the rationale for, and speciﬁcation of, the PRO
outcomes of interest (e.g., mobility, physical function,
HRQOL) in some population of interest (e.g., patients
undergoing initial treatment for breast cancer) for a
particular decision to be made (e.g., choice of appro-
priate chemotherapy); see recommendations of the
Scientiﬁc Advisory Committee of the Medical Out-
comes Trust [7]. In the context of FDA regulatory
decision-making, a conceptual model identiﬁes and
describes the PRO concepts and hypotheses that
underlie a PRO-based product labeling claim.
Guided by an appropriate conceptual model, one
then speciﬁes a corresponding framework for measure-
ment in which all the variables and relationships in the
conceptual model are given operational meaning in a
way that then guides the selection or development of
speciﬁc PRO measurement instruments and psycho-
metric approaches to analysis. In line with FDA rec-
ommendations [6], a conceptual framework focuses
attention on the interrelationships among the PRO
domains being measured, the content validity of each
PRO instrument, and the construct validity, reliability,
and responsiveness of each PRO instrument when
applied within a patient population pertinent to the
product claim.
To convey a sense of how it is challenging to execute
the paradigm suggested above. Most PRO measure-
ment activities reported in the literature have not
sprung from a priori formulated conceptual models,
described, for example by Ferrans [8]. This disconnect
has not gone unnoticed. For example, both Gill and
Feinstein [9] and Leplege and Hunt [10] reported that
the gap is wide between the rhetoric emphasizing that
quality-of-life evaluation must embody the patient’s
perspective and the reality of HRQOL instrumentation
and scoring algorithms. Based on literature reviews,
both articles concluded that measurement models have
frequently reﬂected a professional-judgment orienta-
tion about how to encapsulate what is important to the
patient.
This state of affairs may reﬂect, in part, the absence
of consensus about the appropriate conceptual model
for PRO assessment, as Ferrans [8], Erickson [11],
Darby [12], and Gustafson [13] have emphasized. If so,
a compelling question is how to progress toward such a
consensus––one that serves to improve the motivation,
conduct, and interpretation of PRO measurement.
The simple idea of decision relevance may supply
the key. That is, the selection of a PRO conceptual
model should be guided by the speciﬁc nature of the
decisions that motivate the PRO measurement activity
in the ﬁrst place? For example, the conceptual model
for framing hypotheses relevant to a product claim
for a promising anticancer therapy that also generates
substantial toxicity might emphasize a set of PRO
domains and domain relationships that will differ from
a conceptual model relevant to interventions for pain
management near the end of life. We note that this
deﬁnition of a conceptual model appears closely akin
to the “end point model” that the FDA has presented
subsequent to the publication of the draft guidance
document [14]. Speciﬁcally, the latter is “a model of
the relationships among all measures that may be
deﬁned as end points––primary or supportive––in a
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clinical trial or validation study . . . speciﬁc to a spe-
ciﬁc treatment setting . . . [so as to] inform the instru-
ment development and validation process” [14].
The interconnections among the product claim,
conceptual model for claim analysis, and conceptual
framework(s) for the resulting PRO(s) in the measure-
ment model are discussed in more detail two sections
hence. First we examine the importance of having a
sound conceptual framework for measurement.
What Are the Consequences of Proceeding
with Instrument Selection without a
Well-Established Conceptual Framework
An inadequate conceptual framework for PRO mea-
surement can create challenges for: 1) the grouping and
scoring of items into domains; (2) the analysis; and (3)
the interpretation of PRO scores, all of which are
interrelated and may affect the evaluation of a PRO for
a label claim. First, because items should be grouped
together to represent a clearly deﬁned concept, an
unsuitable conceptual framework can obscure the
grouping and scoring of items into domains. A mis-
guided conceptual framework for measurement, for
example, can lead one to combine items on psychologi-
cal distress “effect indicators” with items that measure
pain, nausea and vomiting, or treatment-related symp-
toms (causal indicators) [15,16]. A patient with high
psychological distress is likely tomanifest a high level of
anxiety. This patient, however, need not necessarily
have high levels of all treatment-related symptoms and
side effects; psychological distress does not necessarily
imply that a patient is experiencing, say, the symptomof
nausea. On the other hand, if a patient does have severe
nausea, then nausea is likely to result in, or cause,
increased psychological distress.
By showing what items belong to speciﬁc domains, a
conceptual framework can enhance clarity in the evalu-
ation of the intended claim. Doing so would help to
avoid the possibility of putting forward an unwarranted
claim based on the performance of an individual item
that, in fact, is merely part of an overall PRO scale. We
therefore concur with the draft guidance that, “Indi-
vidual items that contribute to overall score (e.g.,
dyspnea) generally would not support a dyspnea claim
unless the items were developed to measure the claimed
concept (e.g., the items validly and reliability capture
the impact of treatment on dyspnea)” [6].
The targeted claim should be speciﬁc on which PRO
concepts are being supported or substantiated for
a claim. Particular items should be aggregated into
speciﬁc domains when appropriate. Consider the claim
that “DrugX reduces anxiety and depressionmore than
Drug Y does in adult men with both conditions.” A
plausible conceptual framework for measurement may
encompass items such as feeling tense, feeling panic,
worrying thoughts, and feeling restlessness to measure
the concept of anxiety; and items such as enjoying
things, feeling cheerful, and laughing at things to
measure the concept of depression, with the two con-
cepts posited as being interrelated.
Second, an inadequate conceptual framework can
impair the quality of an analysis. For example, a frame-
work that mixes treatment-related symptoms and func-
tional status could mask the impact of symptoms and
functional status in accounting for observed treatment
differences. Because treatment-related symptoms and
functional status should be grouped and scored sepa-
rately, a conceptual framework that captures this would
lead to an analysis of treatment differences that are
transparent and can be clearly communicated.
Without a well-deﬁned conceptual framework, the
risk of using the wrong psychometric measurement
model is heightened. For instance, analysts might mis-
takenly use exploratory factor analysis instead of con-
ﬁrmatory factor analysis for a conceptual framework
with items that are consequences of disease or treatment
(such as pain, nausea and vomiting, or treatment-
related symptoms) for empiric validation [15,16]. This
distinction is important because such consequences of
disease or treatments, which will be misrepresented as
factors in an exploratory factor analysis, contain little
information about the relationship between the items
and the underlying PRO concepts of interest.
The hypothesized and expected relationships
among concepts can form the basis for a conceptual
framework for measurement before creating the instru-
ment, assessing its measurement properties, and modi-
fying the instrument as needed. Thus, we believe that
empiric evidence from psychometric analyses (e.g.,
exploratory factor analysis) should be used to modify a
conceptual framework as part of a ﬂuid process of
reﬁnement. Modifying a conceptual framework at least
once after a round of creating, assessing, andmodifying
an instrument should become part of an evolving mea-
surement process conducted before a sponsor ﬁles a
new drug application. Such modiﬁcation is intended to
strengthen and hone the hypothesized relationships
with empiric evidence. These enhancements and reﬁne-
ments can lead to an efﬁcient pathway toward a suitable
instrument for evaluating the targeted claim, possibly
leading eventually to an instrument with fewer total
items than the one originally considered. Our position
on this point therefore appears consistent with that in
the FDA draft guidance.
Third, an inadequate conceptual framework can
reduce the interpretability of the measurement model,
because it is not clear what scores obtained from the
instrument represent. Consider the FDAdraft guidance:
“For example, if improvements in a score for a general
concept (e.g., physical function) are driven by a single
responsive domain (e.g., symptom improvement) while
other important domains (e.g., physical abilities and
activities of daily living) did not show a response, a
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general claim about improvements in physical function
would not be supported” [6]. For situations in which
the conceptual framework shows physical functioning
to be validly and reliably measured, and where all items
on the selected physical functioning scale (or all
domains on physical functioning) move in unison, we
believe that a claim about improvement in physical
function would be supported.
In summary, an inappropriate conceptual frame-
work for measurement can hinder the scoring, the
analysis, and the interpretation of a PRO label claim.
Without a well-conceived conceptual framework, the
validation process becomes less structured and there-
fore less likely to empirically support or conﬁrm a
target claim with clarity and precision. A well-deﬁned
conceptual framework, on the other hand, can lead to
a well-deﬁned measurement process in which the ratio-
nale for each PRO instrument (speciﬁcally, for the
instrument’s item content) is clearly articulated and
well-defended in relation to the speciﬁc product claim
being advanced [17].
Having underscored the importance of a sound con-
ceptual framework for measurement, we turn to its
role within an overall model of the application of
PROs to regulatory decision-making.
Application to Regulatory Decision-Making:
Hypothetical Examples?
The FDA’s perspective on the interconnectedness
between the regulatory decision at issue, the concepts to
be measured, and the selection of instrumentation was
illustrated in a recent conference presentation by agency
staff closely involved in development of the emerging
guidance document [18]. In the simple example
employed, the decision is whether and how the FDA
would rule in favor of a particular drug’s desired
claim (“Velpaz relieves pain without upsetting your
stomach”). The posited concepts are “pain relief” and
“stomach upset.” The corresponding measurement
model calls for PRO data derived, respectively, from a
“pain diary” and a “GI-symptom diary.” Some difﬁcult
questions lie just beneath the surface of this compact
depiction of PRO assessment––for example, how to
translate diary-derived data into either single- or mul-
tidimensional scales to measure pain relief and stomach
upset (because the diary itself is just a means to actual
end points) [19]. These are precisely the type of ques-
tions that fully articulated conceptual frameworks for
measurement via a pain diary and a GI-symptom diary
would need to address. The implied linkages among
decision, concept, and measurement are underscored.
This example also suggests that the appropriate
conceptual model for PRO assessment to address a
speciﬁc decision, such as product labeling, will likely
not be identical to one of the comprehensive “concep-
tual models” for HRQOL that depict a host of hypoth-
esized interconnections among outcome dimensions,
clinical variables, and other covariates [20]. For pur-
poses of FDA decision-making, we infer that a concep-
tual model need only be sufﬁciently detailed to clarify,
illuminate, and lend support to the analysis of the PRO
outcomes put forward in the sponsor’s product claim.
In what follows, we illustrate in somewhat more,
albeit ﬁctitious, detail the potential connections among
the product claim, conceptual model, and conceptual
frameworks for guiding the measurement of PROs
germane to the claim.
To demonstrate how the nature and complexity of
the tasks may vary with the scope or breadth of the
product claim, we examine three alternative cases
focusing on the same hypothetical drug, Moodlift,
which is a candidate for FDA approval. The product
is expected to have a positive impact on symptoms of
depression as well as the multiple dimensions of
HRQOL.Nevertheless, early research suggests the drug
is associated with a relatively higher incidence of mild
nausea than the active comparator. The sponsor has
elected to prospectively assess this aspect of tolerability
to allow a more informed and comprehensive assess-
ment of the net beneﬁt of the product. The following
claims range from greater to less complexity:
1. The product claim is for decreased symptoms of
depression and improvement in HRQOL in adult
men with major depressive disorder (MDD).
2. The product claim is for decreased symptoms of
depression and improvement in psychological and
social functioning (a subset of the claim no. 1) in
adult men with MDD.
3. The product claim is for improvement in symp-
toms of depression in adult men with MDD.
In each case, we describe the Product Claim, Con-
ceptualModel, Conceptual Framework(s) forMeasure-
ment, and an illustrative (though ﬁctitious) selection of
PRO measures. After developing Case 1 in detail, we
provide a more concise discussion of Cases 2 and 3,
largely emphasizing the distinctions among the three
cases. Each case essentially reﬂects a different strategy
for seeking labeling approval for a given drug.
Case 1: HRQOL and Symptom Status Claim
Product Claim
Moodlift 20 mg, taken once daily, will lead to
improvement of symptoms of depression and improve-
ment in HRQOL among adult men with MDD.
Conceptual Model for Product Claim Analysis
(see Fig. 1a)
Concepts and domains. Symptoms of depression will
include malaise, feelings of despair and hopelessness,
and impaired decision-making ability. HRQOL will be
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deﬁned as a multidimensional construct with the fol-
lowing domains of functional status: physical, social,
and psychological (which includes emotional function-
ing) [21]. A side effect of Moodlift is increased inci-
dence of mild nausea in relation to the comparator.
Hypothesized relationships:
1. There will be a greater improvement in symptoms
of depression in the treatment group compared to
the active comparator.
2. There will be a greater improvement in social
functioning in the treatment group compared to
the active comparator.
3. There will be a greater improvement in physical
functioning in the treatment group compared to
the active comparator.
4. There will be a greater improvement in a compos-
ite HRQOL index, psychometrically derived from
social, emotional, and physical functioning scores,
compared to the active comparator.
5. There will be greater incidence of mild nausea
in the Moodlift group compared to the active
comparator.
6. Based on the underlying biological mechanisms of
drug efﬁcacy and side effects, improvements in
depression-related symptoms will be positively
A
B
Figure 1 (a) Conceptual model for product
claim analysis: Case 1. (b) Conceptual frame-
work for health-related quality of life (HRQL)
measurement in Case 1 product claim analysis.
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associated with measurable inhibition in serotonin
reuptake, while the occurrence of nausea is posi-
tively associated with drug-induced modulation of
the serotonin receptors lining the patient’s diges-
tive tract.
Conceptual frameworks for measurement of HRQOL,
symptoms of depression and nausea (Figs. 1b and
4). The product claim is for greater improvement in
symptoms of depression and HRQOL than the active
comparator in adult men suffering from MDD.
According to the FDA draft guidance, for an HRQOL
claim to be sustained, improvement must be demon-
strated in each posited HRQOL domain: physical
functioning, social functioning, and psychological
functioning. Thus, the conceptual framework for mea-
surement will focus on the selection, or development,
of measurement scales for physical, social, and psycho-
logical functioning which demonstrate adequate valid-
ity, reliability, and responsiveness when applied to
adult men suffering fromMDD. As in Figure 1b, atten-
tion will be paid to the content validity of the items
measuring each HRQOL domain and the interrela-
tionships among domains.
Although HRQOL is posited here to be multidi-
mensional, common approach is to estimate each
scale separately, using Classical Test Theory or, more
recently, Item Response Theory approaches to select
the optimal item content for each scale. Alternatively,
multidimensional estimation approaches are available
that allow a given item to contribute information to
the estimation of multiple scales [22].
Assuming that improvement on all the three scales
must be demonstrated to support a HRQOL claim, the
conceptual model for measurement does not have to
address a challenging issue: how to judge whether
HRQOL has improved in aggregate for an individual
when some scale scores improve and others worsen in
response to the intervention. This approach assumes
there is strong prior evidence that improvement in each
of the three domains identiﬁed does represent improve-
ment in HRQOL.
The sponsor has taken the unusual approach of
prospectively measuring an aspect of tolerability that is
not expected to be favorable to the product. While an
increased incidence of nausea is expected to be associ-
ated with the product, it is also expected to be mild
and tolerable (only mildly bothersome to subjects).
Prospective assessment of this side effect will allow a
more informed discussion of the beneﬁts and risks (in
this case nausea) of the product.
Finally, an appropriately encompassing conceptual
framework for measurement will impose the same
standards of rigor (validity, reliability, and responsive-
ness in the treatment population relevant to the claim)
on symptom and tolerability outcome measures as on
HRQOL or functional status measures. Such a concep-
tual framework is represented in Figure 4 (which, as
will be seen, is applicable to all three cases here).
PRO instruments. Changes in depressive symptoms
(malaise, despair, and decision-making ability) and
nausea will be measured by domains included in
the MOOD instrument. Changes in physical, social,
and psychological functional status and in overall
HRQOL will be measured by the HEAL measurement
system, which features a multidimensional construct
with distinct domains representing physical, social, and
psychological functioning. In recently published studies
focusing on the treatment of MDD in adult men,
both the MOOD and the HEAL were shown to be
valid, reliable, and responsive measures of symptoms
of depression, nausea related to selective serotonin
reuptake inhibitors (SSRI) use andHRQOL. In particu-
lar, selected domains from the MOODwere good mea-
sures of the depression-related symptoms noted in the
Moodlift claim. Moreover, in these published studies
there was a strong positive correlation between symp-
tom changes as measured by the MOOD, and changes
in physical, social, and psychological functioning as
measured by the scales of the HEAL.
Changes in patient serotonin levels in response to
Moodlift will be measured by the SEROT metric.
SEROT is a well-validated clinical test of serotonin
levels in persons with MDD. It will measure the result-
ing impact on serotonin reuptake and on modulation
of serotonin receptors in the digestive tract.
For patients undergoing treatment with Moodlift,
the hypothesized changes in serotonin-related effects,
symptom status, functional status, and HRQOL will
be estimated using correlation analysis, such as found
in structural equation modeling [22].
Case 2: Functional Status and Symptom
Status Claim
Product Claim
Moodlift 20 mg, taken once daily, will lead to
improvement in symptoms of depression, and psycho-
logical and social functioning among adult men with
MDD.
Conceptual Model for Product Claim Analysis
(see Fig. 2a)
Concepts and domains. Symptoms of depression and
nausea are the same as described in Case 1. Psycho-
logical functioning and social functioning are distinct
domains (constructs) hypothesized to reﬂect the
impact of MDD.
Hypothesized relationships:
1. There will be a greater improvement in symptoms
of depression in the treatment group compared to
the active comparator.
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2. There will be a greater improvement in psycho-
logical functioning in the treatment group com-
pared to the active comparator.
3. There will be a greater improvement in social
functioning in the treatment group compared to
the active comparator.
4. There will be greater incidence of mild nausea
in the Moodlift group compared to the active
comparator.
5. Based on the underlying biological mechanisms of
drug efﬁcacy and side effects, improvements in
depression-related symptoms will be positively
associated with measurable inhibition in serotonin
reuptake, while the occurrence of nausea is posi-
tively associated with drug-induced modulation
of the serotonin receptors lining the patient’s
digestive tract.
Conceptual frameworks for measurement (Figs. 2b
and 4). The product claim is for improvement of
symptoms of depression and in social and psychologi-
cal functioning in adult men with MDD. Thus, the
conceptual framework relevant to Case 2 will focus on
the selection, or development, of measurement scales
for social and psychological functioning that demon-
strate adequate validity (content, construct), reliability,
and responsiveness when applied to adult men suffer-
ing from MDD. As suggested in Figure 2b, there will
be particular attention to the content validity of the
items measuring each domain and the potential inter-
relationships among domains.
Measures and instruments. These will be the same as
in Case 1, with psychological functioning and social
functioning measured by the corresponding scales
from the multidomain HEAL instrument employed in
Case 1. This is justiﬁed by recent published studies
focusing on the treatment of chronic depression in
adult men, in which the social and psychological func-
tioning scales of the HEAL were shown separately to
be valid, reliable, and responsive measures. Moreover,
in these published studies there was a strong positive
correlation between symptom changes, as measured by
the MOOD, and changes in social and psychological
functioning as measured by these scales of the HEAL.
Case 3: Symptom Status Claim
Product Claim
Moodlift 20 mg, taken daily, will lead to improvement
in symptoms of depression in adult men with MDD.
Conceptual Model for Product Claim Analysis
(see Fig. 3)
Concepts and domains. Symptoms of depression will
include malaise, feelings of despair and hopelessness,
and impaired decision-making ability.
Hypothesized relationships:
1. There will be a greater improvement in symptoms
of depression in the treatment group compared to
the active comparator.
2. There will be greater incidence of mild nausea
in the Moodlift group compared to the active
comparator.
3. Based on the underlying biological mechanisms of
drug efﬁcacy and side effects, improvements in
depression-related symptoms will be positively
associated with measurable inhibition in serotonin
reuptake, while the occurrence of nausea is posi-
tively associated with drug-induced modulation
of the serotonin receptors lining the patient’s
digestive tract.
A
B
Figure 2 (a) Conceptual model for product claim analysis: Case 2. (b)
Conceptual framework for functional status measurement in Case 2
product claim analysis.
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Conceptual framework for measurement (Fig. 4). The
same as for the symptom and tolerability measurement
components in Cases 1 and 2.
Measures and instruments. The same as for Cases 1
and 2.
In sum, these examples are intended to illustrate
schematically the execution of the following steps:
1. Identify the product claim, including applicable
population.
2. Deﬁne the conceptual model for product claim
analysis, with all relevant study hypotheses stated.
3. Articulate a conceptual framework for measure-
ment for each PRO concept used in the analysis.
4. Specify the elements of the corresponding mea-
surement model, which operationalizes the con-
ceptual model and is guided in its construction
and testing by the conceptual framework(s).
The principal distinctions between Cases 1, 2, and 3
relate to the breadth and scope of the product claim––
the general approach to laying out the analysis does
not change.
One important working assumption distinguishes
Cases 1 and 2: the proposed principle stated at mul-
tiple points in the FDA draft guidance that to claim an
improvement in HRQOL, there must be concurrent
improvements in all important domains comprising
HRQOL [5]. Thus, under Case 2, if the product
sponsor hypothesized and subsequently found sig-
niﬁcant improvements in psychological and social
functioning––but, contrary to expectations, no signiﬁ-
Figure 3 Conceptual model for product claim analysis: Case 3.
Figure 4 Conceptual framework for symptom
and side-effect measurement in product claim
analysis for Cases 1–3.
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cant change in physical functioning—and if, there was
a signiﬁcant overall improvement in HRQOL (as
assessed through the posited HEAL measurement
system), the HRQOL part of the claim would none-
theless not be allowed. This conclusion apparently
holds even if there are substantial improvements in
psychological and social functioning so that the
HRQOL score improves signiﬁcantly, by either
distribution-based or anchor-based criteria for clinical
signiﬁcance. As long as a product’s claim to improve
HRQOL requires a “dominant solution” (improve-
ment along every HRQOL dimension), there will be a
need for the Case 1–Case 2 distinction as drawn here.
Do Speciﬁc Conceptual Issues Vary or Evolve
by Phase of Product Development (i.e., Phase
I, II, III, or IVTrials)?
In studying new therapeutic areas, investigators have
limited information about how the condition and
treatment affect individuals. Thus, efforts to model
this phenomenon will be limited. As more evidence
becomes available, conceptual models may change by
becoming more elaborate and precise or less complex.
During the process of drug development, considerable
information is obtained that may help inform under-
standing and lead to reﬁnement of models of disease
and treatment. For example, as toxicity data become
available, modiﬁcations to the dosing schedule often
occur. Similarly, we would expect that conceptual
models may evolve over time as new information
becomes available.
The focus of a conceptualmodel at different stages of
product development may also be different. Developing
an elaborate conceptual model describing the impact of
disease and treatment on an individual may be a desir-
able goal in understanding the total illness experience;
doing so, however, may not be useful or desirable in
addressing speciﬁc questions that decision-makers may
pose at different stages of the development process. For
example, in early product development, researchers
need to identify those aspects of patient functioning and
well-being most important to patients and amenable to
therapeutic intervention and to determine the best mea-
sures of those concepts. This may be straightforward in
the case of therapeutic areas that have been studied for
many years, but it may be a more exploratory process
for therapeutic areas that are less well understood.
A conceptual model may help guide selection of
options for investigation. In later stages of develop-
ment, health authorities need to focus on whether the
appropriate end points have been identiﬁed and
whether ﬁndings based on these end points are cor-
rectly interpreted. Following product approval, deter-
mining whether a product should be included in a
formulary may require other information. For ex-
ample, the degree of satisfaction with aspects of a
product in the context of customary care may become
important and should be incorporated into the model.
Greater understanding of a therapeutic area may
also inﬂuence the conceptual framework for measuring
concepts that are identiﬁed over time as relevant to
patients. Addition or deletion of domains or items to
assess domains may be appropriate with more infor-
mation from a larger pool of persons with the condi-
tion under study or application to new conditions.
More data may allow development of abbreviated and
alternative forms or scoring algorithms.
Conclusions
This article addressed four conceptual issues in the
development and use of PRO measures: 1) the deﬁni-
tion of a PRO concept; 2) the description of an
adequate conceptual framework; 3) the consequences
of proceeding with instrument development; and 4) the
variability of conceptual issues over the lifespan of
product development. The potential implication of
these issues for regulatory decision-making was illus-
trated through hypothetical examples that emphasize
the interconnections between the product labeling
claim, the conceptual model guiding the speciﬁcation
of hypotheses, and the conceptual framework guiding
instrument selection or development and data analysis.
We provided no deﬁnitive answers to these ques-
tions. The interpretation and resolution of issues sur-
rounding the measurement of a PRO are evolving as
experience accumulates, but the importance of obtain-
ing the patient’s perspective on the illness experience
is imperative. A conceptual model is important in
guiding our understanding of what to measure and
how to measure it and for providing context for inter-
preting ﬁndings. Such models should be assessed using
psychometric techniques when feasible, although a
fairly advanced level of knowledge in a therapeutic
area may be required to evaluate a more complex
model. Finally, conceptual and measurement models
are not static. As more information becomes available,
our thinking about what to measure and how to
measure it must evolve.
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Glossary
Average-value carried forward An imputation method for missing data which inserts the average response for any missing value.
Cognitive debrieﬁng Asking questions after a survey is completed to determine if there were difﬁculties with the item content or
questions.
Cognitive interview Asking questions to gain understanding as the respondent completes a survey to determine what and how he/she is
thinking.
Conceptual framework Hypothesis of relationships among the domains being researched.
Conceptual model Provides the rationale for and speciﬁcation of the patient-reported outcomes of interest in the population of
interest that will result in a speciﬁc treatment decision.
Differential item functioning Testing to determine whether one group responds differently to an item than another group despite controlling for
differences.
End point model Describes how the end points in a study are expected to interact and justiﬁes the need for their assessment.
Item bank A collection of assessment tools that measure a single domain, have undergone extensive review, and have been
calibrated to a set of properties matching the study population.
Item response theory An approach to assessment construction that involves analysis of individual item responses.
Last-value carried forward An imputation method for missing data which inserts the last value observed for any missing value.
Measurement strategy Using items or instruments designed to assess the domains of interest.
Minimal important difference The smallest change in a patient-reported outcome measure that is perceived by the patient as beneﬁcial or
resulting in a change in treatment.
Zero-value carried forward An imputation method that replaces any missing data with the value zero.
For further deﬁnitions, see the FDA guidance document which includes an extensive glossary (http://www.fda.gov/cder/guidance/5460dft.htm).
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